The timing is interesting. AstraZeneca saw this data: 4/5 responses, 3/5 stringent complete remissions, MRD negativity in all responders from a single injection, and wrote a billion-dollar check. This says that the saw the value.
A second trial (NCT06691685) at Union Hospital is still listed as recruiting, so the program appears to be continuing under the new ownership structure.
There is certainly some safety issues to be resolved. The dosing was incredibly aggressive; all five patients had grade 3+ adverse events. One hyperacute reaction was severe enough that they added preemptive steroids to the protocol mid-trial. The trial death was attributed to disease progression, but it happened during peak CAR-T expansion, which leaves some ambiguity. These are phase 1 problems. But if you’re buying an asset for $1 billion, you’re going to make the clinical study bullet proof.
Thanks for researching that. I wonder if the lawyers prevented the original team from disclosing that as the reason for the trial being stopped, because otherwise it seems like something they'd want to advertise: Look how promising this is! AZ agrees!
Good catch. I replied to this with Fager above. But in short, it looks like restructuring after a $1 billion buyout. But there is some safety in the protocol that may need to be resolved as well.
Exactly. The manufacturing bottleneck is the biggest thing keeping CAR-T out of community practice. An IV-administered vector that ships at scale collapses that entire infrastructure layer. Phase 1, but the architecture is there.
I'd really like to know why they stopped the trial early, and the fact that they didn't disclose that makes me want to know even more.
I looked into this a bit deeper. The trial was stopped because AstraZeneca acquired EsoBiotec in May 2025 for up to $1 billion. The official reason on record is sponsor restructuring. https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html
The timing is interesting. AstraZeneca saw this data: 4/5 responses, 3/5 stringent complete remissions, MRD negativity in all responders from a single injection, and wrote a billion-dollar check. This says that the saw the value.
A second trial (NCT06691685) at Union Hospital is still listed as recruiting, so the program appears to be continuing under the new ownership structure.
There is certainly some safety issues to be resolved. The dosing was incredibly aggressive; all five patients had grade 3+ adverse events. One hyperacute reaction was severe enough that they added preemptive steroids to the protocol mid-trial. The trial death was attributed to disease progression, but it happened during peak CAR-T expansion, which leaves some ambiguity. These are phase 1 problems. But if you’re buying an asset for $1 billion, you’re going to make the clinical study bullet proof.
Thanks for researching that. I wonder if the lawyers prevented the original team from disclosing that as the reason for the trial being stopped, because otherwise it seems like something they'd want to advertise: Look how promising this is! AZ agrees!
Exactly. The tone of this post does not match the fact that you don’t stop a trial that is such a huge success!
Good catch. I replied to this with Fager above. But in short, it looks like restructuring after a $1 billion buyout. But there is some safety in the protocol that may need to be resolved as well.
This would be transformational in our field. This would, in theory, make CAR-T available to community sites.
Exactly. The manufacturing bottleneck is the biggest thing keeping CAR-T out of community practice. An IV-administered vector that ships at scale collapses that entire infrastructure layer. Phase 1, but the architecture is there.
Hey — I came across your writing and really liked how you think.
I’m exploring something similar from a different angle — writing about human behavior through a system design lens (like debugging internal patterns).
Just started publishing on Substack. If you ever get a moment to read, I’d genuinely value your perspective.
Also happy to support your work — feels like there’s an interesting overlap here.